ArticleEmerging infectious diseases2019
Essential Role of Interferon Response in Containing Human Pathogenic Bourbon Virus.
Article in Emerging infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Involvement of a tick-borne orthomyxovirus matrix protein in vRNP nuclear export.Journal of virology · 2025Article
- Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice.Journal of virology · 2025Article
- A novel accessory gene product of tick-borne Dhori-Orthomyxovirus, encoded by overlooked spliced transcripts of RNA segment 6.Journal of virology · 2025Article
- Structure-guided drug repurposing and dynamics simulation reveal anti-viral candidates for Bourbon virus.In silico pharmacology · 2025Article
- Reverse Vaccinology Integrated with Biophysics Techniques for Designing a Peptide-Based Subunit Vaccine for Bourbon Virus.Bioengineering (Basel, Switzerland) · 2024Article
- Cryo-EM structures of Thogoto virus polymerase reveal unique RNA transcription and replication mechanisms among orthomyxoviruses.Nature communications · 2024Article
- Neonatal immune challenge poses a sex-specific risk for epigenetic microglial reprogramming and behavioral impairment.Nature communications · 2023Article
- Geographical distribution and pathogenesis of ticks and tick-borne viral diseases.Frontiers in microbiology · 2023Review
- Comprehensive Review of Emergence and Virology of Tickborne Bourbon Virus in the United States.Emerging infectious diseases · 2023Review
- Bourbon Virus Transmission, New York, USA.Emerging infectious diseases · 2023Article
- Comparative Study of Ten Thogotovirus Isolates and Their DistinctJournal of virology · 2022Article
- Eight years' advances on Bourbon virus, a tick-born Thogotovirus of theZoonoses (Shannon, Ireland) · 2022Article
- Diseases Transmitted by the Black-Legged Ticks in the United States: A Comprehensive Review of the Literature.Cureus · 2021Review
- The expanding spectrum of disease caused by the Lone Star Tick, Amblyomma americanum.Le infezioni in medicina · 2021Review
- Establishment of a Replicon Reporter of the Emerging Tick-Borne Bourbon Virus and Use It for Evaluation of Antivirals.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bourbon virus (BRBV) is a recently discovered tick-transmitted viral pathogen that is prevalent in the Midwest and southern United States. Since 2014, zoonotic BRBV infections have been verified in several human cases of severe febrile illness, occasionally with fatal outcomes, indicating a possible public health threat. We analyzed the pathology of BRBV infection in mice and found a high sensitivity of the virus to the host interferon system. Infected standard laboratory mice did not show clinical signs or virus replication. However, in mice carrying defects in the type I and type II interferon system, the virus grew to high titers and caused severe pathology. In cell culture, BRBV was blocked by antiviral agents like ribavirin and favipiravir (T705). Our data suggest that persons having severe BRBV infection might have a deficiency in their innate immunity and could benefit from an already approved antiviral treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.